Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives

Background/Objectives: Clarithromycin is a common macrolide antibiotic used to treat bacterial infections, but it can be less effective in clinical settings due to its high level of antibiotic resistance and the bitter taste which makes it less palatable to the patient and thus less effective for compliance. The aim of present study was to synthesize and characterize five new derivatives of clarithromycin and check their antibacterial activity and hydrolytic stability to explore the possibility of modifying clarithromycin as an antibacterial agent and/or as a prodrug. Methods: Rational modification of the structure has been used to synthesize five clarithromycin derivatives and characterized by spectroscopic methods. They were assessed for hydrolytic stability at acidic, mildly acidic and physiological pH (pH 2.2, 5.5 and 7.4). The antibacterial activity was measured in the minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC50) against Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. Results: All of our synthesized derivatives showed antibacterial activity which is species dependent. Derivatives exhibited increased activity against P. aeruginosa when compared to clarithromycin. Of the compounds synthesized, Compound 3 (clarithromycin + 3,5-dinitrobenzoyl chloride) exhibited enhanced activity against all four bacterial species. It was active against S. pneumoniae, P. aeruginosa and S. aureus with IC50 values of 0.27 ± 0.03 µg/mL, 0.32 ± 0.22 µg/mL and 0.15 ± 0.04 µg/mL respectively, and some activity against E. coli. Studies of hydrolysis demonstrated that Compound 3 was not observed to regenerate Clarithromycin under the conditions studied, suggesting that it is not a standard prodrug of Clarithromycin. Conclusions: Clarithromycin derivatives with modified antibacterial activities and increased activity against P. aeruginosa were created by structural modification. Instead of regenerating clarithromycin, Compound 3’s antibacterial activity might be linked to the altered molecule and/or its hydrolysis products. These results encourage additional in vivo, pharmacological, and mechanistic research on this derivative.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-19
DOI
https://doi.org/10.3390/antibiotics15111156
Primary Topic
Synthesis and Biological Evaluation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives

Belal Omar Al-Najjar, Haneen Qalalweh, Nadine Mohammed Kamel Qala, Orwah Houshia et al.
Antibiotics
Synthesis and Biological Evaluation
article

Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives

Belal Omar Al-Najjar, Haneen Qalalweh, Nadine Mohammed Kamel Qala, Orwah Houshia, Hatem A. Hijaz
article en

Abstract

Background/Objectives: Clarithromycin is a common macrolide antibiotic used to treat bacterial infections, but it can be less effective in clinical settings due to its high level of antibiotic resistance and the bitter taste which makes it less palatable to the patient and thus less effective for compliance. The aim of present study was to synthesize and characterize five new derivatives of clarithromycin and check their antibacterial activity and hydrolytic stability to explore the possibility of modifying clarithromycin as an antibacterial agent and/or as a prodrug. Methods: Rational modification of the structure has been used to synthesize five clarithromycin derivatives and characterized by spectroscopic methods. They were assessed for hydrolytic stability at acidic, mildly acidic and physiological pH (pH 2.2, 5.5 and 7.4). The antibacterial activity was measured in the minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC50) against Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. Results: All of our synthesized derivatives showed antibacterial activity which is species dependent. Derivatives exhibited increased activity against P. aeruginosa when compared to clarithromycin. Of the compounds synthesized, Compound 3 (clarithromycin + 3,5-dinitrobenzoyl chloride) exhibited enhanced activity against all four bacterial species. It was active against S. pneumoniae, P. aeruginosa and S. aureus with IC50 values of 0.27 ± 0.03 µg/mL, 0.32 ± 0.22 µg/mL and 0.15 ± 0.04 µg/mL respectively, and some activity against E. coli. Studies of hydrolysis demonstrated that Compound 3 was not observed to regenerate Clarithromycin under the conditions studied, suggesting that it is not a standard prodrug of Clarithromycin. Conclusions: Clarithromycin derivatives with modified antibacterial activities and increased activity against P. aeruginosa were created by structural modification. Instead of regenerating clarithromycin, Compound 3’s antibacterial activity might be linked to the altered molecule and/or its hydrolysis products. These results encourage additional in vivo, pharmacological, and mechanistic research on this derivative.

AntibioticsVol. 15(11)
Al-Ahliyya Amman University (JO), Arab American University (PS)
Synthesis and Biological Evaluation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon